PolyPid spikes as Oppenheimer initiates at Outperform on lead asset

What happened

PolyPid shares gained on Tuesday after Oppenheimer started coverage with an Outperform rating and a $10 per share target. The note comes ahead of a Nov. 28 target action date for D-PLEX100, the company's lead asset, which is under FDA priority review.

Confirmed

Global impact / market context

Oppenheimer argues that at an enterprise value near $100 million, investors are undervaluing D-PLEX100, a locally applied antibiotic shown to cut surgical site infections by about 60%. A positive FDA decision could support a hospital launch and change how the market prices the single-asset company.

Analyst inference

The analyst believes the market treats PolyPid as a high-risk, single-asset story despite strong pivotal data and a commercial partner. His model covers only colorectal procedures with incisions over 20 cm, leaving room for upside from a broader label and European partnering.

Analyst inference

What to watch

1. Watch the Nov. 28 target action date, when the FDA is expected to decide on D-PLEX100 under priority review; priority review means a faster review timeline than standard. Confirmed
2. Watch whether PolyPid moves forward with European partnering, new Kynatrix programs, and a broader label for D-PLEX100, which Oppenheimer says could add further upside. Proposed
3. Watch the measured hospital launch expected early next year, with Medicare reimbursements from Q4 2027; reimbursement timing affects revenue and cash available as the company pays for launch costs. Analyst inference

Evidence

• seekingalpha.com